摘要
目的观察尼古丁对BV-2小胶质α7烟碱型乙酰胆碱受体(α7nicotine acetyleholine receptor,α7nAChR)、小胶质细胞P2X4受体(P2X4receptor,P2X4R)表达和脑源性神经营养因子(brain derived neurotrophic factor,BDNF)释放的影响,以探讨小胶质细胞参与尼古丁所致痛觉过敏的可能分子机制。方法①BV-2小胶质细胞接种在含12mm圆形盖玻片无菌12孔板,待细胞处于对数生长期,完全随机分为2组:α7nAChR组和P2X4R组。免疫荧光标记检测α7nAChR和P2X4R在BV-2小胶质细胞上的表达。②当12孔板中BV-2细胞处于对数生长期,完全随机分为4组:尼古丁实验组(N组),尼古丁终浓度为100μm/L;无血清培养基培养的空白对照组(C组);尼古丁拮抗剂组(NM组),10nmol/L甲基牛扁碱(methyllycaconitine,MLA)预孵育30min,改用含尼古丁的无血清培养基培养;单纯拮抗剂组(M组),10nmol/LMLA预孵育30min,改用无血清培养基培养。培养72h后收集各组细胞。应用实时荧光定量PCR(real-timequantitativePCR,RT-qPCR)检测α7nAChRmRNA和P2X4RmRNA表达量的变化,Westernblot检测α7nAChR和P2X4R蛋白表达量的变化。③当12孔板中细胞处于对数生长期,完全随机分为4组:正常对照组(Control组)、尼古丁预处理+DMEM组(Nicotine+DMEM组)、尼古丁预处理+激动剂组(Nieotine+ATP组),尼古丁预处理+拮抗剂组(Nicotine+5-BDBD组)。其中激动剂和拮抗剂由DMEM无血清培养基稀释,在尼古丁处理72h后加入,各组总体积保持一致,24h后ELISA检测培养液中BDNF释放量。结果①免疫荧光标记结果显示BV-2细胞存在α7nAChR和P2X4R的阳性表达。②RT-qPCR结果显示尼古丁可上调BV-2细胞α7nAChRmRNA和P2X4RmRNA的表达,α7nAChR特异性拮抗剂MLA可抑制α7nAChRmRNA和P2X4RmRNA表达的上调;Westernblot结果显示尼古丁处理可使BV-2细胞α7nAChR和P2X4R蛋白的表达上调,α7nAChR特异性拮抗剂MLA可抑制α7nAChR和P2X4R蛋白表达的上调。③ELISA检测培养液中BDNF含量结果显示:Nieofine+ATP组较Nieofine+DMEM组和Control组显著增多(P〈0.05),Nicotine+DMEM组较Control组增多(P〈0.05);Nicotine+5-BDBD组较Nicotine+DMEM组和Control组显著减少(P〈0.05).结论尼古丁可能通过α7nAChR上调小胶质细胞上P2X4R的表达进而通过BDNF的释放引起痛觉过敏的产生。
Objective To observe the expression of α7 nicotine acetylcholine receptor (α7nAChR), P2X4 receptor(P2X4R)and brain derived neurotrophic factor (BDNF) in BV-2 cells after nicotine treatment, and to investigate the molecular mechanism of the involvement of microglia in the nicotine induced pain hypersensitivity. Methods ① BV-2 mieroglial cells were seeded on 12 hole plate that containing 12 mm circular sterile coverslips, the cells in the logarithmic phase were randomly divided into 2 groups: α7nAChR group and P2X4R group. Expression of α7nAChR and P2X4R in BV-2 cells was detected by immunofluorescence staining. ② When BV-2 ceils of 12 well plate in the logarithm growth phase, the eells were randomly divided into 4 groups: nicotine treatment group(Group N), nicotine at a final eoncentration of 100 μmol/L, serum free medium was used as a control group (Group C), nicotine antagonists group(Group NM), pretreatment ceils with methyllycaconitine(MLA) 30 min at a final concentration of 10 nmol/L, then use nicotine treatment cells, simple antagonist group (group M), pretreatment cells with MLA 30 min at a final concentration of 10 nmol/L, then use serum free medium treatment cells, after 72 h, real-time quantitative PCR(RT-qPCR) was used to detect the expression of ot7nAChR mRNA and P2X4R mRNA, and the expression of α7nAChR and P2X4R protein was detected by Western blot. ③ When BV-2 cells of 12 well plate in the logarithm growth phase, the cells were randomly divided into 4 groups: normal control group (Control group) , nicotine pretreatment+DMEM group (Nicotine+DMEM group),nieotine pretreatment+ agonist group(Nicotine+ATP group) , nicotine pretreatmem+antagonist group(Nicotine+5-BDBD group). Agonist and antagonist diluted by DMEM medium without serum. After nicotine treatment 72 h add agonist and antagonist. BDNF released in eultured solution were detected by ELISA after 24 h. Results ① The expression of α7nAChR and P2X4R was founded in BV-2 cells by immunofluorescence staining. ② RT-qPCR results showed that nicotine can up-regulate the expression of α7nAChR mRNA and P2X4R mRNA in BV-2 ceils, and this up-regulation could be inhibited by MLA, a specific antagonist of α7nAChR. Western blot results showed that nicotine can up-regulate the expression of α7nAChR and P2X4R protein in BV-2 cells, and this up-regulation could be inhibited by MLA. ③ ELISA results showed that the content of BDNF in the culture media, the Nicotine+ATP group was significantly increased compared with the Control group and the Nieotine+DMEM group, the Nicotine+DMEM group was increased significantly compared with the Control group, the Nicotine+5-BDBD group was lower than that in the Nicotine+DMEM group and the control group. Conclusions Nicotine may increase the expression of P2X4R through α7nAChR, and then through the release of BDNF to cause hypersensitivity.
出处
《国际麻醉学与复苏杂志》
CAS
2016年第7期606-612,共7页
International Journal of Anesthesiology and Resuscitation
基金
国家自然科学基金(81471134)